Become a Founding Member for $999 a year, locked for life

    Claim a seat
    MavenlyMavenly

    § Federal grant opportunity · RFA-DK-28-113

    Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)

    National Institutes of Health is accepting applications for Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed). The deadline is Rolling / not published and the published award range is Award amount not published.

    Key facts

    Funder
    National Institutes of Health
    Application deadline
    Rolling / not published
    Award range
    Award amount not published
    Eligibility
    city or township governments, other, public and indian housing authorities, public and state institutions of higher education, other native american tribal organizations, nonprofits non higher education without 501c3, small businesses, federally recognized native american tribal governments, special district governments, private institutions of higher education, for profit organizations other than small businesses, nonprofits non higher education with 501c3, independent school districts, state governments, county governments
    Geography
    United States
    Focus areas
    Health
    Opportunity number
    RFA-DK-28-113

    Program overview

    This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches–including organoids, microphysiological systems, and other advanced human-relevant models–to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs. Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from National Institutes of Health.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before Rolling / not published, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.